Celecoxib

Celecoxib:
• selectively inhibits COX-2  mediates inflammation and pain; does not inhibit COX-1  does not affect gastric mucosa and renal function
• well absorbed orally; plasma levels peak in 3 hours; 97% bound to plasma proteins; metabolised in liver  renal excretion; half life is 11 hours
• indicated for osteoarthritis, rheumatoid arthritis
• therapeutic effect is equal to naproxen
• adverse effects – gastrointestinal (less incidence than COX-1 inhibitors); sulphonamide allergy (Celecoxib has a sulfur molecule)
• interactions – Warfarin (increases effect)

Comments are closed.